BrightGene Bio-Medical Technology Co., Ltd. (SHA: 688166)
China flag China · Delayed Price · Currency is CNY
30.20
+0.54 (1.82%)
Jan 6, 2025, 4:00 PM CST

BrightGene Bio-Medical Technology Company Description

BrightGene Bio-Medical Technology Co., Ltd., a pharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products in China.

The company offers Eribulin mesylate injection, Voriconazole for injection, Entecavir tablets, Oseltamivir phosphate capsule and dry suspension, Agatroban injection, Mikafungin sodium for injection, Fondaparinux sodium injection, and Caspofungin acetate for injection.

It also provides antitumor, antibodies drug conjugate, anti-infection, angiography, gynecology, cardiovascular, cerebrovascular, iron supplement, digestion, and other APIs and intermediates.

In addition, the company offers veterinary drugs. BrightGene Bio-Medical Technology Co., Ltd. was founded in 2001 and is based in Suzhou, China.

BrightGene Bio-Medical Technology Co., Ltd.
Country China
Founded 2001
Industry Biotechnology
Sector Healthcare
Employees 1,155
CEO Jiandong Yuan

Contact Details

Address:
Building C25-28
Suzhou, 215123
China
Phone 86 512 6262 0988
Website bright-gene.com

Stock Details

Ticker Symbol 688166
Exchange Shanghai Stock Exchange
Fiscal Year January - December
Reporting Currency CNY
ISIN Number CNE100003PR1
SIC Code 2836

Key Executives

Name Position
Jiandong Yuan Chairman and GM
Yuanlai Zou Chief Financial Officer
Nan Ding Board Secretary
Kai Li Deputy General Manager
Fang Liu Accounting Supervisor